Dr. Hüseyin İstanbullu is an associate professor at the Faculty of Pharmacy, İzmir Katip Çelebi University, where he also serves as vice chair of the Department of Pharmaceutical Chemistry. He earned his Ph.D. in Pharmaceutical Chemistry from Ege University in 2011, following his master’s and bachelor’s degrees from the same institution. His research focuses on the design, synthesis, and biological evaluation of heterocyclic compounds with potential antileishmanial, antineoplastic, and HDAC-inhibitory activities. Dr. İstanbullu has led and contributed to numerous national and international research projects, resulting in publications in high-impact journals and several book chapters. He is an active member of COST Actions, the Royal Society of Chemistry (RSC), and the American Chemical Society (ACS). He is also the recipient of national academic research grants and is a listed inventor on a patent for selective TYK2 inhibitors. His academic contributions extend to graduate and undergraduate teaching in organic and medicinal chemistry.
Research Keywords & Expertise
antibacterial activity
NLRP3 inflammasome
drug design and discov...
antiparasitic compound...
FABP inhibitors
GyraseB inhibitors
Fingerprints
8%
drug design and discovery
8%
FABP inhibitors
Short Biography
Dr. Hüseyin İstanbullu is an associate professor at the Faculty of Pharmacy, İzmir Katip Çelebi University, where he also serves as vice chair of the Department of Pharmaceutical Chemistry. He earned his Ph.D. in Pharmaceutical Chemistry from Ege University in 2011, following his master’s and bachelor’s degrees from the same institution. His research focuses on the design, synthesis, and biological evaluation of heterocyclic compounds with potential antileishmanial, antineoplastic, and HDAC-inhibitory activities. Dr. İstanbullu has led and contributed to numerous national and international research projects, resulting in publications in high-impact journals and several book chapters. He is an active member of COST Actions, the Royal Society of Chemistry (RSC), and the American Chemical Society (ACS). He is also the recipient of national academic research grants and is a listed inventor on a patent for selective TYK2 inhibitors. His academic contributions extend to graduate and undergraduate teaching in organic and medicinal chemistry.
Advance your academic career, collaborate globally, and expand your network—
join now
!
Well done!
